Synovial Sarcoma- Pipeline Insight, 2022

This Synovial-Sarcoma- Pipeline Insight, 2022 report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Synovial-Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Synovial-Sarcoma Understanding

Synovial-Sarcoma: Overview

Synovial sarcoma is a cancer that can come from different types of soft tissue, such as muscle or ligaments. It is often found in the arm, leg, or foot, and near joints such as the wrist or ankle. It can also form in soft tissues in the lung or abdomen. Synovial sarcoma may also be called malignant synovioma.One third of patients with synovial sarcoma will be diagnosed under the age of 30. It is somewhat more common in males. Synovial sarcoma accounts for 5% to 10% of soft-tissue tumors. For every one million people, one to two are diagnosed with synovial sarcoma per year in the US. The symptoms caused by synovial sarcoma depend on where the tumor forms. Synovial sarcoma is often first noticed as a painless lump. If it is near a nerve, it might cause pain or numbness as it grows. Synovial sarcoma is a rare and aggressive soft tissue sarcoma. However, as the tumor grows larger, affected people may notice a lump or swelling. In some cases, the tumor can limit range of motion or cause numbness and/or pain if it presses on nearby nerves. Although Synovial sarcoma does not have a clearly defined cause, genetic factors are believed to influence the development of this disease. Cells in these tumors are usually characterized by the presence of a translocation involving chromosomes X and 18. This translocation is specific to Synovial sarcoma and is often used to diagnose the condition. Treatment for synovial sarcoma depends on whether it has spread. Given that synovial sarcoma can grow for a while before it is found, there is a greater chance that it will spread to other parts of the body. Surgery is the first choice of treatment for synovial sarcomas. When all of the tumor is removed and there is no sign of cancer anywhere else in the body, there is a better chance of survival. Success of the surgery depends on the size of the tumor and its location in the body. Sometimes radiation therapy is used before or after surgery to kill cancer cells. Chemotherapy may be used when synovial sarcoma cannot be completely removed by surgery or when it has spread. Researchers are working to develop new treatments for synovial sarcomas. Some are in clinical trials.

Synovial-Sarcoma- Pipeline Insight, 2022 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Synovial-Sarcoma pipeline landscape is provided which includes the disease overview and Synovial-Sarcoma treatment guidelines. The assessment part of the report embraces, in depth Synovial-Sarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Synovial-Sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Synovial-Sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Synovial-Sarcoma.

Synovial-Sarcoma Emerging Drugs Chapters

This segment of the Synovial-Sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Synovial-Sarcoma Emerging Drugs

CFT 8634: C4 Therapeutics

CFT8634 is a BiDAC™ degrader targeting BRD9 for the treatment of cancers that are dependent on BRD9, including synovial sarcoma and SMARCB1 deleted cancers. However, C4T's TORPEDO® platform was leveraged to discover CFT8634, an orally bioavailable, selective degrader of BRD9. Unlike BRD9 inhibition, BRD9 degradation is efficacious in preclinical models of synovial sarcoma. In December 2021, the FDA cleared C4T's investigational new drug (IND) application for CFT8634 to proceed with the proposed Phase 1/2 trial in patients with synovial sarcoma and SMARCB1-null solid tumors.

FHD 609: Foghorn Therapeutics

FHD-609, is a protein degrader of BRD9. BRD9 is a component of one form of the BAF complex. Nearly all synovial sarcoma cancers contain a translocation, a type of mutation, between a BAF subunit gene, SS18, and another set of genes. This mutation causes cancer cells to rely on BRD9 for their survival.FHD-609 has two domains: one that binds to BRD9 and the other that binds to a complex that directs proteins for destruction. By targeting BRD9 for degradation, FHD-609 depletes a key subunit of the BAF complex that is required for the survival of cancer cells. The drug is currently in Phase I stage of Clinical trial evaluation for the treatment of Synovial sarcoma.

BA-3011: BioAtla

BA3011, CAB-AXL-ADC, a conditionally and reversibly active antibody drug conjugate targeting the receptor tyrosine kinase AXL, as a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC) and ovarian cancer, with other potential indications in the future. The Office of Orphan Drug Products (OODP) at FDA granted Orphan Drug Designation to BA3011 for the treatment of soft tissue sarcoma, and Phase I results in sarcoma patients were presented at the recent Connective Tissue Oncology Society (CTOS) 2021 Annual Meeting. BA3011 was generally well tolerated in this refractory sarcoma population. Few patients discontinued due to an adverse event (2 patients out of 26 or 7.7%). No clinically meaningful on-target toxicity to normal AXL-expressing tissue was observed.

Synovial-Sarcoma: Therapeutic Assessment

This segment of the report provides insights about the different Synovial-Sarcoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Synovial-Sarcoma

There are approx. 14+ key companies which are developing the therapies for Synovial-Sarcoma. The companies which have their Synovial-Sarcoma drug candidates in the most advanced stage, i.e. phase II include, BioAtla.

Phases

This report covers around 14+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Synovial-Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Synovial-Sarcoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Synovial-Sarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Synovial-Sarcoma drugs.

Synovial-Sarcoma Report Insights

• Synovial-Sarcoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Synovial-Sarcoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Synovial-Sarcoma drugs?
• How many Synovial-Sarcoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Synovial-Sarcoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Synovial-Sarcoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Synovial-Sarcoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• BioAtla
• C4 Therapeutics
• Foghorn Therapeutics
• OncoTherapy Science
• Adaptimmune
• Incyte Corporation
• PharmaMar

Key Players

• FHD 609
• CFT 8634
• BA-3011
• OTSA101-DTPA-111In
• afamitresgene autoleucel
• Itacitinib
• Lurbinectedin

This product will be delivered within 1-3 business days.